+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Macromolecular Single-target Angiogenesis Inhibitor Market - Global Forecast 2026-2032- Product Image
Macromolecular Single-target Angiogenesis Inhibitor Market - Global Forecast 2026-2032- Product Image
Sale

Macromolecular Single-target Angiogenesis Inhibitor Market - Global Forecast 2026-2032

  • Report

  • 193 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6151134
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Macromolecular Single-target Angiogenesis Inhibitor Market is projected to reach USD 1.93 Billion in 2026. It is expected to continue growing at a CAGR of 6.39%, reaching USD 2.81 Billion by 2032.

Introduction to Macromolecular Single-target Angiogenesis Inhibitors

Macromolecular single-target angiogenesis inhibitors are biologic medicines designed to block a defined signaling pathway involved in new blood-vessel formation. Their relevance spans oncology, ophthalmology, and other diseases in which abnormal vascular growth contributes to progression. Evaluation of this field depends on clinical evidence, regulatory status, treatment administration, biomarker strategy, safety monitoring, and the ability of healthcare systems to deliver specialized biologic therapy.

Transformative Shifts in Targeted Angiogenesis Inhibition

The landscape is shifting from broad antiangiogenic approaches toward more selective biologic intervention, combination treatment, and biomarker-informed patient selection. Longer-acting delivery systems, improved injection and infusion workflows, and greater attention to treatment persistence are also changing product-development priorities. At the same time, regulators and providers are placing stronger emphasis on comparative clinical benefit, meaningful patient outcomes, immunogenicity management, and evidence that supports use across diverse care settings.

How Artificial Intelligence Is Reshaping Development and Care

Artificial intelligence can support this field by identifying vascular and molecular patterns in imaging, prioritizing biological targets, improving trial recruitment, and helping researchers characterize response and resistance. In clinical practice, machine-learning tools may assist with image interpretation, treatment monitoring, and patient-risk stratification. However, reliable deployment requires representative datasets, prospective validation, transparent performance assessment, protection of patient data, and clinical oversight; AI should complement rather than replace specialist judgment.

Regional Insights Across the Global Landscape

North America is characterized by advanced biologic development capabilities, specialized treatment centers, and sophisticated reimbursement evaluation. Europe combines strong translational research with detailed health-technology assessment and varied national access pathways. Asia-Pacific includes major research and manufacturing ecosystems alongside substantial differences in regulatory maturity and healthcare access. Latin America is shaped by uneven specialist capacity, procurement constraints, and the importance of adaptable delivery models. The Middle East is investing in advanced healthcare infrastructure, while Africa continues to face challenges involving diagnostics, specialist availability, affordability, and reliable supply. Across all regions, evidence generation and implementation must reflect local care pathways rather than assume uniform access.

Group-Level Perspectives: ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN presents a diverse mix of regulatory systems, healthcare capacity, and cross-border supply requirements, making regional harmonization valuable. BRICS includes large and varied patient populations, domestic biopharmaceutical capabilities, and differing approaches to approval, procurement, and reimbursement. The European Union benefits from collaborative scientific and regulatory structures but retains national variation in healthcare financing. G7 systems generally offer strong research infrastructure and pharmacovigilance capacity, while also scrutinizing affordability and comparative effectiveness. GCC countries are expanding tertiary-care capabilities and may benefit from coordinated procurement and specialist networks. NATO members are not a uniform healthcare bloc, but their research, preparedness, and supply-chain relationships can influence resilience for complex biologic therapies.

Country Insights for Selected National Healthcare Systems

The United States combines deep clinical-trial capacity with complex payer and provider decision-making. Canada emphasizes public-system assessment, provincial implementation, and equitable access. The United Kingdom relies on centralized evidence and value evaluation alongside specialized services. Germany, France, Italy, and Spain operate within European regulatory structures while differing in assessment, reimbursement, and regional delivery. Australia balances strong clinical research with geographic dispersion. Japan and South Korea have advanced medical and manufacturing capabilities with distinct regulatory and reimbursement requirements. China is strengthening domestic innovation and regulatory capacity while managing broad regional variation. India combines expanding biotechnology expertise with pronounced differences in affordability and access. Brazil, Mexico, and Russia face the additional importance of public procurement, local manufacturing considerations, and uneven specialist availability.

Actions for Leaders in Macromolecular Angiogenesis Inhibition

Industry leaders should build development programs around clinically meaningful endpoints, clearly defined target biology, and evidence that demonstrates durable patient benefit. Early planning should include companion diagnostics where useful, diverse trial populations, immunogenicity surveillance, and practical administration requirements. Access strategies should account for reimbursement evidence, cold-chain reliability, trained providers, and alternative delivery settings. Organizations should also establish responsible AI governance, strengthen real-world evidence capabilities, engage regulators and health systems early, and design supply networks that can withstand regional disruption without compromising quality.

Research Methodology for the Executive Summary

This executive summary uses a structured qualitative review of the defined market scope: macromolecular therapies directed at a single angiogenic target. The assessment framework considers mechanism of action, clinical and regulatory development, treatment delivery, evidence requirements, healthcare-system readiness, regional conditions, and the potential role of artificial intelligence. Geographic interpretation integrates North America, Latin America, Europe, the Middle East, Africa, and Asia-Pacific, with additional discussion of the specified country and group contexts. Claims are framed at a strategic level and intentionally exclude market estimates, sizing, shares, forecasts, and company-specific analysis.

Conclusion: Building Evidence and Access Around Targeted Biologics

Macromolecular single-target angiogenesis inhibitors sit at the intersection of precision biology, biologic medicine, and specialized care delivery. Progress will depend not only on demonstrating target engagement, but also on selecting appropriate patients, managing safety, simplifying treatment pathways, and proving value to health systems. Regional and national differences make adaptable evidence and access strategies essential. Leaders that combine rigorous clinical science with responsible technology use, resilient supply planning, and implementation-focused partnerships will be best positioned to translate targeted angiogenesis inhibition into meaningful patient outcomes.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Macromolecular Single-target Angiogenesis Inhibitor Market, by Molecular Structure
7.1. Introduction
7.2. Monoclonal Antibody
7.3. Recombinant Fusion Protein
8. Macromolecular Single-target Angiogenesis Inhibitor Market, by Target Molecule
8.1. Introduction
8.2. Fibroblast Growth Factor
8.3. Platelet Derived Growth Factor
8.4. Vascular Endothelial Growth Factor
8.4.1. Oncology
8.4.1.1. Breast Cancer
8.4.1.2. Colorectal Cancer
8.4.1.3. Non Small Cell Lung Cancer
8.4.2. Ophthalmology
8.4.2.1. Age Related Macular Degeneration
8.4.2.2. Diabetic Macular Edema
8.4.2.3. Retinal Vein Occlusion
9. Macromolecular Single-target Angiogenesis Inhibitor Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Intravitreal
9.4. Subcutaneous
10. Macromolecular Single-target Angiogenesis Inhibitor Market, by End User
10.1. Introduction
10.2. Hospital And Clinic
10.3. Specialty Center
11. Macromolecular Single-target Angiogenesis Inhibitor Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Macromolecular Single-target Angiogenesis Inhibitor Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Macromolecular Single-target Angiogenesis Inhibitor Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. AB Scence
15.2. Amgen Inc.
15.3. AstraZeneca plc
15.4. Bayer AG
15.5. Bristol-Myers Squibb Company
15.6. Eisai Co., Ltd.
15.7. Eli Lilly and Company
15.8. Exelixis, Inc.
15.9. F. Hoffmann-La Roche Ltd
15.10. Genentech, Inc.
15.11. GlaxoSmithKline plc
15.12. ImClone LLC
15.13. Johnson & Johnson
15.14. Merck & Co., Inc.
15.15. Novartis AG
15.16. OSI Pharmaceuticals
15.17. Pfizer Inc.
15.18. Pro Chon Biotech
15.19. Regeneron Pharmaceuticals Inc.
15.20. Taiho Pharmaceutical Co., Ltd.
15.21. Wyeth
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Macromolecular Single-target Angiogenesis Inhibitor Market, Years Considered for the Study
FIGURE 2. Global Macromolecular Single-target Angiogenesis Inhibitor Market, Research Design
FIGURE 3. Global Macromolecular Single-target Angiogenesis Inhibitor Market, Research Framework
FIGURE 4. Global Macromolecular Single-target Angiogenesis Inhibitor Market, Data Triangulation
FIGURE 5. Global Macromolecular Single-target Angiogenesis Inhibitor Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Molecular Structure, 2025 vs 2032 (%)
FIGURE 7. Global Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Molecular Structure, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Target Molecule, 2025 vs 2032 (%)
FIGURE 9. Global Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Target Molecule, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 11. Global Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Macromolecular Single-target Angiogenesis Inhibitor Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Macromolecular Single-target Angiogenesis Inhibitor Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Macromolecular Single-target Angiogenesis Inhibitor Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Macromolecular Single-target Angiogenesis Inhibitor Market Segmentation & Coverage
TABLE 2. Global Macromolecular Single-target Angiogenesis Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 3. Global Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Molecular Structure, 2017-2032 (USD Million)
TABLE 4. Global Monoclonal Antibody Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Monoclonal Antibody Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Monoclonal Antibody Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Recombinant Fusion Protein Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Recombinant Fusion Protein Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Recombinant Fusion Protein Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Target Molecule, 2017-2032 (USD Million)
TABLE 11. Global Fibroblast Growth Factor Market Size, by Region, 2017-2032 (USD Million)
TABLE 12. Global Fibroblast Growth Factor Market Size, by Group, 2017-2032 (USD Million)
TABLE 13. Global Fibroblast Growth Factor Market Size, by Country, 2017-2032 (USD Million)
TABLE 14. Global Platelet Derived Growth Factor Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Platelet Derived Growth Factor Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Platelet Derived Growth Factor Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Vascular Endothelial Growth Factor Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Vascular Endothelial Growth Factor Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Vascular Endothelial Growth Factor Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Breast Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Breast Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Breast Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Colorectal Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Colorectal Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Colorectal Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Non Small Cell Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Non Small Cell Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Non Small Cell Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Ophthalmology Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Ophthalmology Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Ophthalmology Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Age Related Macular Degeneration Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Age Related Macular Degeneration Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Age Related Macular Degeneration Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Diabetic Macular Edema Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Diabetic Macular Edema Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Diabetic Macular Edema Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Retinal Vein Occlusion Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Retinal Vein Occlusion Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Retinal Vein Occlusion Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 45. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Intravitreal Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Intravitreal Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Intravitreal Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Macromolecular Single-target Angiogenesis Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 55. Global Hospital And Clinic Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Hospital And Clinic Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Hospital And Clinic Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Specialty Center Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Specialty Center Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Specialty Center Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Asia-Pacific Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Asia-Pacific Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Molecular Structure, 2017-2032 (USD Million)
TABLE 64. Asia-Pacific Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Target Molecule, 2017-2032 (USD Million)
TABLE 65. Asia-Pacific Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Vascular Endothelial Growth Factor, 2017-2032 (USD Million)
TABLE 66. Asia-Pacific Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 67. Asia-Pacific Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 68. Asia-Pacific Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 69. Asia-Pacific Macromolecular Single-target Angiogenesis Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 70. North America Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. North America Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Molecular Structure, 2017-2032 (USD Million)
TABLE 72. North America Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Target Molecule, 2017-2032 (USD Million)
TABLE 73. North America Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Vascular Endothelial Growth Factor, 2017-2032 (USD Million)
TABLE 74. North America Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 75. North America Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 76. North America Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 77. North America Macromolecular Single-target Angiogenesis Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 78. Latin America Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Latin America Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Molecular Structure, 2017-2032 (USD Million)
TABLE 80. Latin America Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Target Molecule, 2017-2032 (USD Million)
TABLE 81. Latin America Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Vascular Endothelial Growth Factor, 2017-2032 (USD Million)
TABLE 82. Latin America Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 83. Latin America Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 84. Latin America Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 85. Latin America Macromolecular Single-target Angiogenesis Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 86. Europe Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Europe Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Molecular Structure, 2017-2032 (USD Million)
TABLE 88. Europe Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Target Molecule, 2017-2032 (USD Million)
TABLE 89. Europe Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Vascular Endothelial Growth Factor, 2017-2032 (USD Million)
TABLE 90. Europe Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 91. Europe Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 92. Europe Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 93. Europe Macromolecular Single-target Angiogenesis Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 94. Middle East Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 95. Middle East Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Molecular Structure, 2017-2032 (USD Million)
TABLE 96. Middle East Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Target Molecule, 2017-2032 (USD Million)
TABLE 97. Middle East Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Vascular Endothelial Growth Factor, 2017-2032 (USD Million)
TABLE 98. Middle East Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 99. Middle East Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 100. Middle East Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 101. Middle East Macromolecular Single-target Angiogenesis Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 102. Africa Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 103. Africa Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Molecular Structure, 2017-2032 (USD Million)
TABLE 104. Africa Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Target Molecule, 2017-2032 (USD Million)
TABLE 105. Africa Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Vascular Endothelial Growth Factor, 2017-2032 (USD Million)
TABLE 106. Africa Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 107. Africa Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 108. Africa Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 109. Africa Macromolecular Single-target Angiogenesis Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 110. Global Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 111. ASEAN Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 112. ASEAN Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Molecular Structure, 2017-2032 (USD Million)
TABLE 113. ASEAN Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Target Molecule, 2017-2032 (USD Million)
TABLE 114. ASEAN Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Vascular Endothelial Growth Factor, 2017-2032 (USD Million)
TABLE 115. ASEAN Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 116. ASEAN Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 117. ASEAN Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 118. ASEAN Macromolecular Single-target Angiogenesis Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 119. GCC Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 120. GCC Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Molecular Structure, 2017-2032 (USD Million)
TABLE 121. GCC Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Target Molecule, 2017-2032 (USD Million)
TABLE 122. GCC Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Vascular Endothelial Growth Factor, 2017-2032 (USD Million)
TABLE 123. GCC Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 124. GCC Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 125. GCC Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 126. GCC Macromolecular Single-target Angiogenesis Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 127. European Union Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 128. European Union Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Molecular Structure, 2017-2032 (USD Million)
TABLE 129. European Union Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Target Molecule, 2017-2032 (USD Million)
TABLE 130. European Union Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Vascular Endothelial Growth Factor, 2017-2032 (USD Million)
TABLE 131. European Union Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 132. European Union Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 133. European Union Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 134. European Union Macromolecular Single-target Angiogenesis Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 135. BRICS Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 136. BRICS Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Molecular Structure, 2017-2032 (USD Million)
TABLE 137. BRICS Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Target Molecule, 2017-2032 (USD Million)
TABLE 138. BRICS Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Vascular Endothelial Growth Factor, 2017-2032 (USD Million)
TABLE 139. BRICS Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 140. BRICS Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 141. BRICS Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 142. BRICS Macromolecular Single-target Angiogenesis Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 143. G7 Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 144. G7 Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Molecular Structure, 2017-2032 (USD Million)
TABLE 145. G7 Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Target Molecule, 2017-2032 (USD Million)
TABLE 146. G7 Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Vascular Endothelial Growth Factor, 2017-2032 (USD Million)
TABLE 147. G7 Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 148. G7 Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 149. G7 Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 150. G7 Macromolecular Single-target Angiogenesis Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 151. NATO Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 152. NATO Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Molecular Structure, 2017-2032 (USD Million)
TABLE 153. NATO Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Target Molecule, 2017-2032 (USD Million)
TABLE 154. NATO Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Vascular Endothelial Growth Factor, 2017-2032 (USD Million)
TABLE 155. NATO Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 156. NATO Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 157. NATO Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 158. NATO Macromolecular Single-target Angiogenesis Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 159. Global Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Country, 2017-2032 (USD Million)
TABLE 160. United States Macromolecular Single-target Angiogenesis Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 161. United States Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Molecular Structure, 2017-2032 (USD Million)
TABLE 162. United States Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Target Molecule, 2017-2032 (USD Million)
TABLE 163. United States Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Vascular Endothelial Growth Factor, 2017-2032 (USD Million)
TABLE 164. United States Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 165. United States Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 166. United States Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 167. United States Macromolecular Single-target Angiogenesis Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 168. Canada Macromolecular Single-target Angiogenesis Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 169. Canada Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Molecular Structure, 2017-2032 (USD Million)
TABLE 170. Canada Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Target Molecule, 2017-2032 (USD Million)
TABLE 171. Canada Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Vascular Endothelial Growth Factor, 2017-2032 (USD Million)
TABLE 172. Canada Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 173. Canada Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 174. Canada Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 175. Canada Macromolecular Single-target Angiogenesis Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 176. Mexico Macromolecular Single-target Angiogenesis Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 177. Mexico Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Molecular Structure, 2017-2032 (USD Million)
TABLE 178. Mexico Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Target Molecule, 2017-2032 (USD Million)
TABLE 179. Mexico Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Vascular Endothelial Growth Factor, 2017-2032 (USD Million)
TABLE 180. Mexico Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 181. Mexico Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 182. Mexico Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 183. Mexico Macromolecular Single-target Angiogenesis Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 184. Brazil Macromolecular Single-target Angiogenesis Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 185. Brazil Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Molecular Structure, 2017-2032 (USD Million)
TABLE 186. Brazil Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Target Molecule, 2017-2032 (USD Million)
TABLE 187. Brazil Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Vascular Endothelial Growth Factor, 2017-2032 (USD Million)
TABLE 188. Brazil Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 189. Brazil Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 190. Brazil Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 191. Brazil Macromolecular Single-target Angiogenesis Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 192. United Kingdom Macromolecular Single-target Angiogenesis Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 193. United Kingdom Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Molecular Structure, 2017-2032 (USD Million)
TABLE 194. United Kingdom Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Target Molecule, 2017-2032 (USD Million)
TABLE 195. United Kingdom Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Vascular Endothelial Growth Factor, 2017-2032 (USD Million)
TABLE 196. United Kingdom Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 197. United Kingdom Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 198. United Kingdom Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 199. United Kingdom Macromolecular Single-target Angiogenesis Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 200. Germany Macromolecular Single-target Angiogenesis Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 201. Germany Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Molecular Structure, 2017-2032 (USD Million)
TABLE 202. Germany Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Target Molecule, 2017-2032 (USD Million)
TABLE 203. Germany Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Vascular Endothelial Growth Factor, 2017-2032 (USD Million)
TABLE 204. Germany Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 205. Germany Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 206. Germany Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 207. Germany Macromolecular Single-target Angiogenesis Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 208. France Macromolecular Single-target Angiogenesis Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 209. France Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Molecular Structure, 2017-2032 (USD Million)
TABLE 210. France Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Target Molecule, 2017-2032 (USD Million)
TABLE 211. France Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Vascular Endothelial Growth Factor, 2017-2032 (USD Million)
TABLE 212. France Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 213. France Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 214. France Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 215. France Macromolecular Single-target Angiogenesis Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 216. Russia Macromolecular Single-target Angiogenesis Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 217. Russia Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Molecular Structure, 2017-2032 (USD Million)
TABLE 218. Russia Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Target Molecule, 2017-2032 (USD Million)
TABLE 219. Russia Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Vascular Endothelial Growth Factor, 2017-2032 (USD Million)
TABLE 220. Russia Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 221. Russia Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 222. Russia Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 223. Russia Macromolecular Single-target Angiogenesis Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 224. Italy Macromolecular Single-target Angiogenesis Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 225. Italy Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Molecular Structure, 2017-2032 (USD Million)
TABLE 226. Italy Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Target Molecule, 2017-2032 (USD Million)
TABLE 227. Italy Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Vascular Endothelial Growth Factor, 2017-2032 (USD Million)
TABLE 228. Italy Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 229. Italy Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 230. Italy Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 231. Italy Macromolecular Single-target Angiogenesis Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 232. Spain Macromolecular Single-target Angiogenesis Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 233. Spain Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Molecular Structure, 2017-2032 (USD Million)
TABLE 234. Spain Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Target Molecule, 2017-2032 (USD Million)
TABLE 235. Spain Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Vascular Endothelial Growth Factor, 2017-2032 (USD Million)
TABLE 236. Spain Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 237. Spain Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 238. Spain Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 239. Spain Macromolecular Single-target Angiogenesis Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 240. China Macromolecular Single-target Angiogenesis Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 241. China Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Molecular Structure, 2017-2032 (USD Million)
TABLE 242. China Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Target Molecule, 2017-2032 (USD Million)
TABLE 243. China Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Vascular Endothelial Growth Factor, 2017-2032 (USD Million)
TABLE 244. China Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 245. China Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 246. China Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 247. China Macromolecular Single-target Angiogenesis Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 248. India Macromolecular Single-target Angiogenesis Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 249. India Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Molecular Structure, 2017-2032 (USD Million)
TABLE 250. India Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Target Molecule, 2017-2032 (USD Million)
TABLE 251. India Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Vascular Endothelial Growth Factor, 2017-2032 (USD Million)
TABLE 252. India Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 253. India Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 254. India Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 255. India Macromolecular Single-target Angiogenesis Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 256. Japan Macromolecular Single-target Angiogenesis Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 257. Japan Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Molecular Structure, 2017-2032 (USD Million)
TABLE 258. Japan Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Target Molecule, 2017-2032 (USD Million)
TABLE 259. Japan Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Vascular Endothelial Growth Factor, 2017-2032 (USD Million)
TABLE 260. Japan Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 261. Japan Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 262. Japan Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 263. Japan Macromolecular Single-target Angiogenesis Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 264. Australia Macromolecular Single-target Angiogenesis Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 265. Australia Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Molecular Structure, 2017-2032 (USD Million)
TABLE 266. Australia Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Target Molecule, 2017-2032 (USD Million)
TABLE 267. Australia Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Vascular Endothelial Growth Factor, 2017-2032 (USD Million)
TABLE 268. Australia Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 269. Australia Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 270. Australia Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 271. Australia Macromolecular Single-target Angiogenesis Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 272. South Korea Macromolecular Single-target Angiogenesis Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 273. South Korea Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Molecular Structure, 2017-2032 (USD Million)
TABLE 274. South Korea Macromolecular Single-target Angiogenesis Inhibitor Market Size, by Target Molecule, 2017-2032 (USD Million)
TABLE 275. South Korea Macromole

Companies Mentioned

  • AB Scence
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • GlaxoSmithKline plc
  • ImClone LLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • OSI Pharmaceuticals
  • Pfizer Inc.
  • Pro Chon Biotech
  • Regeneron Pharmaceuticals Inc.
  • Taiho Pharmaceutical Co., Ltd.
  • Wyeth

Related Topics

Related Reports

Small Molecule Multi-target Angiogenesis Inhibitor Market - Global Forecast 2026-2032 - Product Image

Small Molecule Multi-target Angiogenesis Inhibitor Market - Global Forecast 2026-2032

  • Report
  • 186 Pages
  • Global
From
Oral Complement Inhibitors Market - Global Forecast 2026-2032 - Product Image

Oral Complement Inhibitors Market - Global Forecast 2026-2032

  • Report
  • 199 Pages
  • Global
From
Complement Inhibitors Market (2nd Edition): Distribution by Target Disease Indication, Therapeutic Area, Type of Molecule, Target Pathway, Type of Therapy, Route of Administration, Leading Drugs, Key Geographical Regions and Leading Players - Trends and Forecast Till 2035 - Product Image

Complement Inhibitors Market (2nd Edition): Distribution by Target Disease Indication, Therapeutic Area, Type of Molecule, Target Pathway, Type of Therapy, Route of Administration, Leading Drugs, Key Geographical Regions and Leading Players - Trends and Forecast Till 2035

  • Report
  • 131 Pages
  • Global
From
Factor XII Inhibitors Market Report 2026 - Product Image

Factor XII Inhibitors Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Paroxysmal Nocturnal Hemoglobinuria - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Paroxysmal Nocturnal Hemoglobinuria - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 169 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.